Proceeds from website advertising help sustain Lab Tests Online. AACC is a not-for-profit organization and does not endorse non-AACC products and services.


Print this article
Share this page:
Also known as: Promyelocytic Leukemia/Retinoic Acid Receptor Alpha [PML-RARA t(15;17)(q22;q12)]
Formal name: [PML-RARA t(15;17)]

At a Glance

Why Get Tested?

To help diagnose acute promyelocytic leukemia (APL), a type of acute myeloid leukemia (AML); to help guide and/or monitor treatment of APL or to monitor for recurrence

When to Get Tested?

When you have results of a CBC and/or signs and symptoms that suggest that you may have leukemia; periodically when you are being treated for APL and/or when you are in remission

Sample Required?

A blood sample drawn from a vein in your arm or a bone marrow sample collected using a bone marrow aspiration and/or biopsy procedure

Test Preparation Needed?


The Test Sample

What is being tested?

Promyelocytic leukemia/retinoic acid receptor alpha or PML-RARA refers to an abnormal gene sequence that is associated with a specific type of leukemia. This test detects and measures PML-RARA in the blood or bone marrow to determine if an individual has acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). PML-RARA represents the rearrangement of genetic material on two chromosomes.

Humans normally have 23 pairs of chromosomes, including 22 pairs of non-sex-determining chromosomes (also known as autosomes) and 1 pair of sex chromosomes (XX for females, XY for males). Chromosomes contain a person's inherited genetic information. The genes that reside there form the blueprints for the production of thousands of proteins. Sometimes changes can occur to a person's chromosomes and/or genes during their lifetime because of exposures to radiation, toxins, or for unknown reasons.

The PML-RARA gene sequence is one such acquired change (mutation) that is formed when pieces of chromosome 15 and chromosome 17 break off and switch places. The PML gene region in chromosome 15 then fuses with the RARA gene region in chromosome 17. This is referred to as reciprocal translocation, and this particular one is commonly expressed as t(15;17).

Normally, the PML gene codes for a protein that helps prevent uncontrolled cell growth and acts as a tumor suppressor. The RARA gene codes for a protein that is crucial for white blood cell (WBC) maturation, as these cells typically develop through several stages in the bone marrow before release into circulation. The mutated PML-RARA fusion gene codes for an abnormal fusion protein that does neither of these functions but instead leads to the uncontrolled production and accumulation of leukemic WBCs that do not mature or differentiate beyond the promyelocyte stage. As a large number of these abnormal cells start to crowd out the normal blood cell precursors in the bone marrow, signs and symptoms of leukemia start to emerge.

Up to 98% of cases of acute promyelocytic leukemia have a characteristic t(15;17) PML-RARA reciprocal chromosomal translocation. Occasionally, cases of APL have translocations involving the RARA gene and genes other than PML.

Testing detects the PML-RARA fusion gene or its transcripts, the RNA copies made by the cell from the abnormal gene sequence of DNA. The presence of the PML-RARA abnormality helps confirm the diagnosis of APL.

Testing can also help guide cancer therapy. Treatment of APL typically involves all-trans retinoic acid (ATRA), a drug that binds to retinoic acid receptors on cells. The drug can overcome the effect of the abnormal PML-RARA protein and allow the WBCs to continue maturing. This therapy works well in conjunction with chemotherapy but only in those cases where the PML-RARA fusion gene is present. The treatment results in remission in about 80-90% of these patients, according to the American Cancer Society. A small percentage of people with APL have a fusion between the RARA gene and a different gene, and they may or may not benefit from ATRA therapy dependending upon the specific gene involved.

There are several different types of PML-RARA tests available, including:

  • Fluorescence in situ hybridization (FISH)
    This test method uses fluorescent dye-labeled probes to "light up" the PML-RARA gene sequence when it is present. This method also determines the percentage of blood or bone marrow cells that contain the abnormal, fused PML-RARA gene. FISH can also be used to detect the variant translocations involving RARA and genes other than PML. This may help identify ATRA-resistant rearrangements.
  • Genetic molecular testing
    The polymerase chain reaction (PCR)-based tests detect and quantify PML-RARA gene transcripts, or gene product units, in a person's blood and/or bone marrow samples. The PML-RARA PCR test is quantitative, that is, it provides a general estimate of the number of PML-RARA gene sequences present.
  • Chromosome analysis (cytogenetics or karyotyping)
    This test method involves the evaluation of a person's chromosomes under a microscope to detect structural and/or numerical abnormalities. Cells in a sample of blood or bone marrow are examined to determine if the PML-RARA t(15;17) chromosome translocation is present. Other chromosomal abnormalities, such as translocations involving the RARA gene and genes other than PML can also be detected.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm or a bone marrow sample is collected using a bone marrow aspiration and/or biopsy procedure.

NOTE: If undergoing medical tests makes you or someone you care for anxious, embarrassed, or even difficult to manage, you might consider reading one or more of the following articles: Coping with Test Pain, Discomfort, and Anxiety, Tips on Blood Testing, Tips to Help Children through Their Medical Tests, and Tips to Help the Elderly through Their Medical Tests.

Another article, Follow That Sample, provides a glimpse at the collection and processing of a blood sample and throat culture.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed.

The Test

Common Questions

Ask a Laboratory Scientist

Form temporarily unavailable

Due to a dramatic increase in the number of questions submitted to the volunteer laboratory scientists who respond to our users, we have had to limit the number of questions that can be submitted each day. Unfortunately, we have reached that limit today and are unable to accept your inquiry now. We understand that your questions are vital to your health and peace of mind, and recommend instead that you speak with your doctor or another healthcare professional. We apologize for this inconvenience.

This was not an easy step for us to take, as the volunteers on the response team are dedicated to the work they do and are often inspired by the help they can provide. We are actively seeking to expand our capability so that we can again accept and answer all user questions. We will accept and respond to the same limited number of questions tomorrow, but expect to resume the service, 24/7, as soon as possible.

Article Sources

« Return to Related Pages

NOTE: This article is based on research that utilizes the sources cited here as well as the collective experience of the Lab Tests Online Editorial Review Board. This article is periodically reviewed by the Editorial Board and may be updated as a result of the review. Any new sources cited will be added to the list and distinguished from the original sources used.

Seiter, K. (Updated 2012 March 9). Acute Myelogenous Leukemia. Medscape Reference [On-line information]. Available online at through Accessed May 2013.

Yang, J. and Schiffer, C. (2012). Genetic Biomarkers in Acute Myeloid Leukemia. Medscape Today News from Expert Rev Hematol. 2012;5(4):395-407. [On-line information]. Available online at through Accessed May 2013.

Mason, J. and Griffiths, M. (2012). Molecular Diagnosis of Leukemia. Medscape Today News from Expert Rev Mol Diagn. 2012;12(5):511-526. [On-line information]. Available online at through Accessed May 2013.

Kelley, T. and South, S. (2013 March). Acute Myeloid Leukemia – AML. ARUP Consult [On-line information]. Available online at through Accessed May 2013.

(© 1995–2013). PML/RARA Quantitative, PCR. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at through Accessed May 2013.

(Reviewed 2011 April). Acute promyelocytic leukemia. Genetics Home Reference [On-line information]. Available online at through Accessed April 2013.

(Reviewed 2011 April). RARA. Genetics Home Reference [On-line information]. Available online at through Accessed April 2013.

Kelley, T. and Schumacher, J. (2012 August). PML-RARA , t(15;17) Quantitation by RT-PCR ARUP. ARUP Laboratories [On-line information]. PDF available for download at;17%29QuantitationbyRT-PCR.pdf through Accessed April 2013.

VanderWalde, A. and Vora, N. (2012 June 18). Genetics of Acute Myeloid Leukemia Medscape Reference [On-line information]. Available online at through Accessed April 2013.

Kotiah, S. and Besa, E. (Updated 2011 August 2). Acute Promyelocytic Leukemia Medscape Reference [On-line information]. Available online at through Accessed April 2013.

Polampalli, S., et. al. (2011) Role of RT-PCR and FISH in diagnosis and monitoring of acute promyelocytic leukemia. Indian J Cancer v 48:60-7. Available online through Accessed May 2013.

Nasr, R. Et. al. (2009) Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure. Clin Cancer Res v 15:6321-6326. [On-line information]. Available online at through Accessed April 2013.

Ommen, H. et. al. (2010 January 14). Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood v 115 (2) 198-205 [On-line information]. Available online at through Accessed April 2013.

(Reviewed 2011 December). PML/RARA t(15;17) Translocation, FISH and Quantitative Real-Time PCR. Quest Diagnostics [On-line information]. Available online at through Accessed May 2013.